Medicare AdvantageCoverageLow impact
MA08.186, Penpulimab-kcqx
Independence Blue Cross·Oncology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.186 for Penpulimab-kcqx (a cancer immunotherapy drug) has been established. This creates new coverage and billing guidelines for this specialty oncology medication under Medicare Advantage plans.
Action Required
By December 29, 2025: Oncology billing teams should access the full policy at the provided URL to review specific coverage criteria, prior authorization requirements, and billing procedures for Penpulimab-kcqx. Update drug formulary references and prior auth workflows as specified in the complete policy.